Toby M. Maher
YOU?
Author Swipe
View article: Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial Open
Background We investigated the prognostic potential of circulating biomarkers at baseline and the effects of nintedanib on changes in these biomarkers in subjects with progressive pulmonary fibrosis (PPF). Methods In the INBUILD trial, sub…
View article: Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an <i>AJRCCM</i> Special Section
Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an <i>AJRCCM</i> Special Section Open
View article: Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis: Findings from ISABELA Clinical Trials
Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis: Findings from ISABELA Clinical Trials Open
Background Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of pulmonary function and poor survival. Although biomarkers for disease progression and mortality exist, their reliability in large studies remains unprov…
View article: A dose-finding pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults
A dose-finding pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults Open
Background Deupirfenidone, a selectively deuterated form of pirfenidone, is being developed for idiopathic pulmonary fibrosis (IPF), where tolerability limits current antifibrotic use. Deupirfenidone retains the biological activity of pirf…
View article: Cardiac Stereotactic Body Radiation Therapy (SBRT) for Refractory Ventricular Tachycardia Using Innovative Motion Tracking With Electroanatomical Mapping and CyberKnife Synchrony
Cardiac Stereotactic Body Radiation Therapy (SBRT) for Refractory Ventricular Tachycardia Using Innovative Motion Tracking With Electroanatomical Mapping and CyberKnife Synchrony Open
View article: LB0003 EFFICACY AND SAFETY OF NERANDOMILAST IN PATIENTS WITH AUTOIMMUNE DISEASE–RELATED PROGRESSIVE PULMONARY FIBROSIS: SUBGROUP ANALYSIS OF THE FIBRONEER-ILD TRIAL
LB0003 EFFICACY AND SAFETY OF NERANDOMILAST IN PATIENTS WITH AUTOIMMUNE DISEASE–RELATED PROGRESSIVE PULMONARY FIBROSIS: SUBGROUP ANALYSIS OF THE FIBRONEER-ILD TRIAL Open
View article: Risk of acute pericarditis after pulsed-field ablation pulmonary vein isolation
Risk of acute pericarditis after pulsed-field ablation pulmonary vein isolation Open
Rates of PFA PAP are higher than initially estimated and similar to RFA PAP, with similar risk factors.
View article: Kappa and Mu Opioid Receptors in Chronic Cough: Current Evidence and Future Treatment
Kappa and Mu Opioid Receptors in Chronic Cough: Current Evidence and Future Treatment Open
Chronic cough is a significant burden on patient quality of life and is associated with poor health outcomes. Chronic cough may be a result of neural hypersensitivity due to changes in both the peripheral and the central nervous systems, a…
View article: Artificial Intelligence and the Diagnosis of Interstitial Lung Disease: Are We Ready for <scp>ChatMDT</scp>?!
Artificial Intelligence and the Diagnosis of Interstitial Lung Disease: Are We Ready for <span>ChatMDT</span>?! Open
See related article
View article: Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosis
Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosis Open
Background Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition that is more prevalent in males than females. The reasons for this are not fully understood; differing environmental exposures due to historically sex-biased occupa…
View article: Home is where spirometry should be: enhancing care for individuals with pulmonary fibrosis
Home is where spirometry should be: enhancing care for individuals with pulmonary fibrosis Open
Home spirometry is an important tool for monitoring patients with pulmonary fibrosis. Modern handheld spirometers combined with web-based platforms permit minimally intrusive, patient-centric measurement of FVC, providing clinically imp…
View article: Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis
Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis Open
Introduction Proof-of-concept (POC) studies are vital in determining the feasibility of further drug development, primarily by assessing preliminary efficacy signals with credible endpoints. However, traditional POC studies in idiopathic p…
View article: Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation Open
Instituto de Salud Carlos III; Instituto Tecnológico y de Eenergías Renovables; Cabildo Insular de Tenerife; Fundación DISA; National Heart, Lung, and Blood Institute of the US National Institutes of Health; and UK Medical Research Council.
View article: Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non‐Responders in <scp>IPF</scp>?
Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non‐Responders in <span>IPF</span>? Open
See related article
View article: Phase 2 Study Design and Analysis Approach for BBT-877: An Autotaxin Inhibitor Targeting Idiopathic Pulmonary Fibrosis
Phase 2 Study Design and Analysis Approach for BBT-877: An Autotaxin Inhibitor Targeting Idiopathic Pulmonary Fibrosis Open
Introduction Proof-of-concept (POC) studies are vital in determining the feasibility of further drug development, primarily by assessing preliminary efficacy signals with credible endpoints. However, traditional POC studies in idiopathic p…
View article: Publisher Correction: Fibrosis: cross-organ biology and pathways to development of innovative drugs
Publisher Correction: Fibrosis: cross-organ biology and pathways to development of innovative drugs Open
View article: Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications
Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications Open
Introduction The pathophysiology of respiratory complications in post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) is poorly understood, but a high incidence of progressive pulmonary fibro…
View article: Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets Open
Background Idiopathic pulmonary fibrosis (IPF) is a rare, incurable lung disease with a median survival of 3-5 years after diagnosis. Treatment options are limited. Genetic association studies can identify new genes involved in disease tha…
View article: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial
The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial Open
Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease frequently complicated by gastro-oesophageal reflux disease. Although several observational studies and a pilot study have investigated the rol…
View article: Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosis
Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosis Open
Background Prostasin is expressed in the lung epithelium where it regulates fluid and electrolyte balance via sodium channel proteolysis. We investigated whether circulating prostasin levels are associated with the presence and severity of…
View article: Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease Open
Objective: Safe, effective therapies are urgently needed for patients with systemic sclerosis. However, clinical trial recruitment is challenging given the limited number of people with systemic sclerosis and further restrictions imposed b…
View article: A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease
A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease Open
View article: Rare variants and survival of patients with idiopathic pulmonary fibrosis
Rare variants and survival of patients with idiopathic pulmonary fibrosis Open
Background The clinical course of idiopathic pulmonary fibrosis (IPF) is highly variable and unpredictable, with multiple genetic variants influencing IPF outcomes. Notably, rare pathogenic variants in telomere-related genes are associated…
View article: Managing Silicosis in the United States
Managing Silicosis in the United States Open
Once considered a disease of the past in developed countries, silicosis is making a worrying comeback as an irreversible and potentially fatal pulmonary disease in the United States. Silicosis has been an unfortunate mainstay of respirator…
View article: Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis Open
Background Biomarkers that change in response to nintedanib in subjects with idiopathic pulmonary fibrosis (IPF) would be valuable. We investigated the effects of nintedanib on circulating biomarkers in subjects with IPF in the INMARK tria…
View article: Pioneering Research Driving Progress toward a Cure for Interstitial Lung Disease (ILD): Introduction to the <i>AJRCCM</i> Special Issue on ILD (Part 2)
Pioneering Research Driving Progress toward a Cure for Interstitial Lung Disease (ILD): Introduction to the <i>AJRCCM</i> Special Issue on ILD (Part 2) Open
View article: Competing Causes of Death in Idiopathic Pulmonary Fibrosis
Competing Causes of Death in Idiopathic Pulmonary Fibrosis Open
View article: Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation
Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation Open
None.
View article: The future of clinical trials in idiopathic pulmonary fibrosis
The future of clinical trials in idiopathic pulmonary fibrosis Open
Purpose of review Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis and limited therapeutic options. A multitude of promising compounds are currently being investigated; however, the design and conduct…
View article: Genetic burden of dysregulated cytoskeletal organisation in the pathogenesis of pulmonary fibrosis
Genetic burden of dysregulated cytoskeletal organisation in the pathogenesis of pulmonary fibrosis Open
Background Pulmonary fibrosis (PF) is a shared characteristic of chronic interstitial lung diseases of mixed aetiology. Previous studies on PF highlight a pathogenic role for common and rare genetic variants. This study aimed to identify r…